Jim Cramer, the host of Mad Money, cautioned viewers on Wednesday about the risks of blindly following the crowd in the stock ...

GMO's portfolio update highlights key stock adjustments and forecasts a promising 9.6% return for International Deep Value ...

Tweedy Browne’s 13F portfolio value decreased from $2.10B to $1.48B. Click here to read more about the trades and holdings of ...

Johnson & Johnson (NYSE:JNJ) is a healthcare company engaged in the research, development, manufacturing, and marketing of a ...

Compared to the aggregate P/E ratio of the 27.1 in the Pharmaceuticals industry, Johnson & Johnson Inc. has a lower P/E ratio ...

Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ...

Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently sold shares of the company's stock. According to a recent SEC filing, Wolk sold 13,015 ...

Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently executed significant stock transactions according to a recent SEC filing. On February 7, ...

Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

Check out today's top DJIA stocks, including Nvidia, JPMorgan, and Visa. See key trends, price targets, and market insights ...